Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative dataStephen B. Williams, Jerome P. Richie, David W. McDermott et al.|British Journal of Urology|2009Cited by 71
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapyKendrick Yim, Mark A. Preston, Affan Zafar et al.|Urologic Oncology Seminars and Original Investigations|2023Cited by 31
Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular CancerStephen B. Williams, Jerome P. Richie, David W. McDermott et al.|The Journal of Urology|2009Cited by 23
Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.Xiao X. Wei, Guru Sonpavde, Bradley A. McGregor et al.|Journal of Clinical Oncology|2020Cited by 20
Predictors of Positive Retroperitoneal Lymph Nodes in Patients With High Risk Testicular CancerStephen B. Williams, John P. Richie, Ravi Kacker et al.|The Journal of Urology|2011Cited by 15